ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2171

A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers
Abstract Number: 2172

A Novel Cohort to Assess Longitudinal Glucocorticoid Toxicity in Individuals with Rheumatic Diseases: Objectives, Design, and Initial Baseline Characteristics
Abstract Number: 2173

Hope and Health in Adolescents with Chronic Musculoskeletal Pain
Abstract Number: 2174

Current Treatment of Macrophage Activation Syndrome Worldwide: The METAPHOR Project, a PReS/PRINTO Real-life International Survey
Abstract Number: 2175

Pediatric Rheumatology Clinic Referral Patterns at a Large Midwestern Center
Abstract Number: 2176

Applying Similarity Network Fusion to Identify Patient Clusters for People with Systemic Inflammatory Disease
Abstract Number: 2177

CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients
Abstract Number: 2178

Evaluating the Non-Inferiority of Mycophenolate Mofetil Compared to Methotrexate in Treating Juvenile Localized Scleroderma
Abstract Number: 2179

Evaluation of Diagnostic Concordance Between Telehealth Encounters and In-Person Follow-up Assessments in Pediatric Rheumatology
Abstract Number: 2180

The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis
Abstract Number: 2181

Large Pediatric Cohort with ANCA-associated Vasculitis at a Single Institution: Patient Characteristics, Clinical Course, and Outcomes
Abstract Number: 2182

PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Abstract Number: 2183

Accuracy of AI Tools for Diagnosis of Connective Tissue Disease
Abstract Number: 2184

Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE
Abstract Number: 2185

TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, a Feasibility Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].